MedNous recently sat down with the scientific and clinical leads at One‑carbon Therapeutics to explore how renewed attention on one‑carbon metabolism is reshaping the therapeutic landscape for hard‑to‑treat solid tumours. The feature traces the company’s journey from fundamental metabolic biology to a first‑in‑human programme, detailing how dysregulated folate flux, formate overflow and MTHFD1/2 activity create exploitable vulnerabilities in cancer cells — vulnerabilities that One‑carbon is now targeting with its first‑in‑class dual inhibitor, TH9619.

The article highlights how TH9619’s folate‑trapping mechanism selectively induces nucleotide shortage and DNA damage in tumour cells while sparing normal tissue, and how the ongoing ODIN Phase 1/2 study is designed to translate this biology into clinical impact for patients with advanced refractory cancers. With European sites actively enrolling and mechanistic data continuing to build, One‑carbon outlines why one‑carbon metabolism may represent one of the most promising new frontiers in precision oncology.

To read the full analysis of the science, strategy and clinical path ahead, access the complete MedNous article.